The reasons may include the migration of CABG to PCI and major advances in medical management (application of the statin drugs, as evidenced by the COURAGE trial,3 angiotensin-converting enzyme inhibitors [ACE-I] for secondary prevention,4,5 progressively more effective “anti-platelet” drugs, enhanced control of hypertension, etc) coupled with increasingly effective diagnostic modalities, supported by increasingly accurate prognostic data, enabling progressively more effective identification of patients at risk who may require particularly intensive management strategies. Here, ACE is linked to hypertensive disorder.